Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.42 |
| ▸ | FEN1 | P39748 | 2/20 | 0.42 |
| ▸ | BRAF | P15056 | 5/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29769075 | 0.90 | KDR (0.46) | KDRALOX5APFEN1BRAFLOXL2 | |
| SCHEMBL14662000 | 0.90 | KDR (0.46) | KDRALOX5APFEN1BRAFLOXL2 | |
| SCHEMBL29769056 | 0.85 | LOXL2 (0.40) | KDRALOX5APFEN1LOXL2LOX | |
| SCHEMBL24998894 | 0.85 | LOXL2 (0.40) | KDRALOX5APFEN1LOXL2LOX | |
| SCHEMBL24999602 | 0.83 | AR (0.45) | KDR | |
| SCHEMBL24999942 | 0.83 | LOXL2 (0.43) | KDRALOX5APFEN1BRAFLOXL2 | |
| SCHEMBL29769124 | 0.83 | LOXL2 (0.43) | KDRALOX5APFEN1BRAFLOXL2 | |
| SCHEMBL876505 | 0.82 | PLAAT3 (0.43) | S1PR1S1PR3 | |
| SCHEMBL9104846 | 0.80 | S1PR1 (0.36) | S1PR1S1PR3PPARD | |
| SCHEMBL24998880 | 0.78 | KDR (0.46) | KDRALOX5APFEN1BRAFTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230044787-A1 | TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230044787-A1 | TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | LYPLAL1, LYPLA1, LYPLA2 | KDR 3060/4885ALOX5AP 54/4885FEN1 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.